Alyeska Investment Group L.P. Has $42.11 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Alyeska Investment Group reduced its Xenon Pharmaceuticals stake by 46.3% in the second quarter, selling 601,777 shares and retaining 697,692 shares worth approximately $42.1 million. Institutional investors collectively own 95.45% of the company.
• Analysts remain broadly positive, with Xenon receiving an average “Buy” rating and a consensus price target of $77.13, despite some target-price reductions and one “Sell” rating.
• XENE shares opened at $59.99, while recent insider activity was negative as directors sold shares totaling about $774,000 over three months. The company reported a quarterly loss of $1.11 per share, slightly better than the expected $1.16 loss.

Alyeska Investment Group L.P. trimmed its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 46.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 697,692 shares of the biopharmaceutical company's stock after selling 601,777 shares during the period. Alyeska Investment Group L.P. owned about 0.72% of Xenon Pharmaceuticals worth $42,113,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Hsbc Holdings PLC boosted its stake in shares of Xenon Pharmaceuticals by 24.6% during the 2nd quarter. Hsbc Holdings PLC now owns 151,474 shares of the biopharmaceutical company's stock worth $9,143,000 after buying an additional 29,916 shares during the last quarter. Palo Alto Investors LP bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $3,099,184. PenderFund Capital Management Ltd. acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $413,000. Capstone Investment Advisors LLC bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $539,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at about $2,084,000. 95.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Needham & Company LLC cut their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Royal Bank Of Canada lowered their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $77.13.

Insider Buying and Selling

In other news, Director Steven Gannon sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the completion of the sale, the director owned 1,870 shares in the company, valued at $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the company's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is owned by company insiders.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $59.99 on Monday. Xenon Pharmaceuticals Inc. has a 1-year low of $35.60 and a 1-year high of $72.66. The stock has a 50-day moving average of $63.18 and a 200-day moving average of $56.48. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -12.66 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same period in the prior year, the firm earned ($1.07) EPS. Sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source